Biogen (NASDAQ:BIIB) and City Therapeutics signed a collaboration to develop novel RNA interference ((RNAi)) therapies ...

Biogen will pay City Therapeutics $46m, which includes $16m upfront and $30m investment for a convertible note.

A start-up that launched only 8 months ago has attracted the attention of Biogen, a major developer of neurological drugs.

Results from a clinical trial led by researchers from Queen Mary University of London, published today in JAMA, show that ...

Collaboration leverages City Therapeutics’ next-generation RNAi engineering technologies and Biogen’s extensive drug ...

ADARx Pharmaceuticals will work with AbbVie to make RNA interference medicines for a variety of disease areas, including ...

TransCode Therapeutics (NASDAQ: RNAZ) , has appointed Dr. Phillip D. Zamore, a leading figure in RNA interference (RNAi) research and co-founder of A ...

TransCode Therapeutics, Inc. (Nasdaq: RNAZ), a clinical-stage oncology company developing RNA-targeted therapeutics for the treatment of cancer, today announced the appointment of Phillip D. Zamore, ...

Biotech major Biogen (Nasdaq: BIIB) and fellow Cambridge, USA-based City Therapeutics, today announced a strategic ...

Researchers discovered that two neighboring genes, old and zao, regulate antiviral responses and symptom expression in the ...

TransCode Therapeutics (NASDAQ: RNAZ) , has appointed Dr. Phillip D. Zamore, a leading figure in RNA interference (RNAi) research and co-founder of A ...